Corporate News  
PRESS RELEASE – 2017/08/03

STADA shows good operational development in first six months of 2017

  • Significant increase in Group sales (+10 percent), EBITDA (+10 percent) and net income (+10 percent)
  • Strong growth and significant margin improvement in Generics – sales (+8 percent), EBITDA (+17 percent), EBITDA margin (+180 basis points)
  • Significant growth in Branded Products – sales (+15 percent), EBITDA (+16 percent)
  • Improvement in net debt to adjusted EBITDA ratio to 2.3

Bad Vilbel, 2017/08/03
– “STADA’s operational development in the first six months of 2017 was good. We achieved growth that was well into the double digits in the Belgian Generics segment and in the Russian Branded Products segment. In addition to the strong sales growth, we were also able to further increase profitability”, says STADA’s Chairman of the Executive Board Engelbert Coster Tjeenk Willink.

Read the full press release with all the facts and figures on our website.
To the press release

All the best
Your STADA Corporate Communications
  Go to the News
  More News  

STADANews Service
To cancel or change your subscription to the newsletter, please click the following link: cancel/change mail service subscription.
STADA Arzneimittel AG
Stadastraße 2-18
61118 Bad Vilbel
Corporate Communications
Phone +49 (0)6101 603-113
Fax +49 (0)6101 603-215

© STADA Arzneimittel AG, Stadastraße 2-18, 61118 Bad Vilbel, Phone: +49 (0) 6101 603-0, Fax: +49 (0) 06101 603-259,, e-Mail:

Executive Board: Engelbert Coster Tjeenk Willink (Chairman) | Dr. Bernhard Düttmann | Dr. Barthold Piening
Supervisory Board: Carl Ferdinand Oetker (Chairman)
Company´s headquarters: Bad Vilbel, District Court: Frankfurt am Main HR B 71290

This e-mail may contain confidential and/or privileged information. If you are not the intended recipient or if you have received this e-mail in error, please notify the sender immediately and delete this e-mail. Any unauthorized copying, disclosure or distribution of the contents of this e-mail is strictly prohibited.

Please do not answer this email.